Targretin — Competitive Intelligence Brief

Targretin (BEXAROTENE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Retinoid [EPC]. Area: Oncology.

marketed Retinoid [EPC] Retinoic acid receptor RXR-beta Oncology Small molecule

Target snapshot

Targretin (BEXAROTENE) — Bausch Health. Targretin works by binding to the retinoic acid receptor RXR-beta, which helps regulate cell growth and differentiation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Targretin TARGET	BEXAROTENE	Bausch Health	marketed	Retinoid [EPC]	Retinoic acid receptor RXR-beta	1999-01-01
Sohonos	PALOVAROTENE	Ipsen	marketed	Retinoid [EPC]	Retinoic acid receptor gamma	2023-01-01
TRIFAROTENE	TRIFAROTENE		marketed	Retinoid [EPC]		2019-01-01
Panretin	ALITRETINOIN	Advanz	marketed	Retinoid [EPC]	Retinoic acid receptor beta	1999-01-01
Soriatane	ACITRETIN	Stiefel Labs Inc	marketed	Retinoid [EPC]	Bile salt export pump	1996-01-01
Differin	ADAPALENE	Galderma Labs Lp	marketed	Retinoid [EPC]	Retinoic acid receptor beta	1996-01-01
Tegison	ETRETINATE		marketed	Retinoid	Retinoic acid receptor RXR-gamma	1986-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2026-09-15 — Differin · 8435502 · Formulation · US
• 2026-09-15 — Differin · 8709392 · Formulation · US
• 2028-05-31 — Differin · 7998467 · Formulation · US

Sponsor landscape (Retinoid [EPC] class)

1. Bausch Health · 2 drugs in this class
2. · 2 drugs in this class
3. Chulalongkorn University · 1 drug in this class
4. Galderma Labs Lp · 1 drug in this class
5. Ipsen · 1 drug in this class
6. Padagis LLC · 1 drug in this class
7. Stiefel Labs Inc · 1 drug in this class
8. Advanz · 1 drug in this class